Renagel®:: reducing serum phosphorus in haemodialysis patients

被引：4

作者：

Burke, SK ^{[1
]}

机构：

[1] GelTex Pharmaceut Inc, Clin Res, Waltham, MA 02451 USA

来源：

HOSPITAL MEDICINE | 2000年 / 61卷 / 09期

关键词：

D O I：

10.12968/hosp.2000.61.9.1419

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Approximately half of all dialysis patients experience persistent hyperphosphataemia, which causes significant problems. Renagel(R) is a calcium-free, aluminium-free phosphate binder which reduces serum phosphorus in haemodialysis patients by reducing absorption of dietary phosphorus. This article reviews the management of hyperphosphataemia and presents some Renagel(R) clinical trial data.

引用

页码：622 / 627

页数：6

共 24 条

[1] A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients [J].

Bleyer, AJ ;

Burke, SK ;

Dillon, M ;

Garrett, B ;

Kant, KS ;

Lynch, D ;

Rahman, SN ;

Schoenfeld, P ;

Teitelbaum, I ;

Zeig, S ;

Slatopolsky, E .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) :694-701

[2] Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].

Block, GA ;

Hulbert-Shearon, TE ;

Levin, NW ;

Port, FK .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617

[3] METABOLIC BALANCE STUDIES AND DIETARY-PROTEIN REQUIREMENTS IN PATIENTS UNDERGOING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS [J].

BLUMENKRANTZ, MJ ;

KOPPLE, JD ;

MORAN, JK ;

COBURN, JW .

KIDNEY INTERNATIONAL, 1982, 21 (06) :849-861

[4] Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients [J].

Braun, J ;

Oldendorf, M ;

Moshage, W ;

Heidler, R ;

Zeitler, E ;

Luft, FC .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :394-401

[5] RenaGel(R), a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers [J].

Burke, SK ;

Slatopolsky, EA ;

Goldberg, DI .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1640-1644

[6]

Chertow GM, 1999, CLIN NEPHROL, V51, P18

[7] Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure [J].

Chertow, GM ;

Burke, SK ;

Lazarus, JM ;

Stenzel, KH ;

Wombolt, D ;

Goldberg, D ;

Bonventre, JV ;

Slatopolsky, E .

AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (01) :66-71

[8] Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients [J].

Chertow, GM ;

Burke, SK ;

Dillon, MA ;

Slatopolsky, E .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (12) :2907-2914

[9]

Collins A., 1999, Journal of the American Society of Nephrology, V10, p607A

[10] PHOSPHORUS AND PROTEIN RESTRICTION AND PARATHYROID FUNCTION IN CHRONIC-RENAL-FAILURE [J].

COMBE, C ;

APARICIO, M .

KIDNEY INTERNATIONAL, 1994, 46 (05) :1381-1386

← 1 2 3 →